Invivoscribe LymphoTrack Dx IVD Assays now available
Abacus dx is pleased to inform you that the Invivoscribe LymphoTrack Dx IVD Assays are now available.
20Jul
20Jul
Idylla ctBRAF Mutation Assay (Research Use Only)
A revolution in liquid biopsy cancer research.
20Jul
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Biocartis is pleased to announce the publication of an important study [1] by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
20Jul
Idylla EGFR Mutation Test (CE-IVD)
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
20Jul
Biocartis Idylla BRAF Mutation Test
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.
20Jul
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Press Release: Mechelen, Belgium, 27 June 2018
20Jul
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
16Jul
Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).
16Jul
A uniquely designed ALK/EML4 TriCheck FISH probe for lung cancer diagnosis
ZytoVision’s ZytoLight products allow for reliable, highly sensitive and specific detection of genetic aberrations (e.g. translocations, deletions, amplifications and chromosomal aneuploidies) by using fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears, and metaphase chromosome spreads.